These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 21619856)

  • 21. Current challenges in viral safety and extraneous agent testing.
    Mackay D; Kriz N
    Biologicals; 2010 May; 38(3):335-7. PubMed ID: 20338787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing risks--challenges posed by the European general product safety directive.
    van Aken D
    Inj Control Saf Promot; 2002 Sep; 9(3):151-6. PubMed ID: 12462167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent developments in the risk assessment of potentially genotoxic impurities in pharmaceutical drug substances.
    Humfrey CD
    Toxicol Sci; 2007 Nov; 100(1):24-8. PubMed ID: 17656486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. European project concerning the guidelines on medicinal products derived from human blood and plasma.
    Horaud F
    Dev Biol Stand; 1991; 75():237-40. PubMed ID: 1794627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quality criteria of homoeopathic mother tinctures: considerations regarding suitable tests for homoeopathic monographs.
    Biber A; Franck-Karl G; Klein G; Stumpf KH
    Pharmeur Sci Notes; 2005 Aug; 2005(1):53-9. PubMed ID: 17687895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. European Regulatory guidance on virus safety of recombinant proteins, monoclonal antibodies and plasma derived medicinal products.
    Celis P; Silvester G
    Dev Biol (Basel); 2004; 118():3-10. PubMed ID: 15645667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Issues related to harmonization of testing requirements for viral safety.
    Hayakawa T
    Dev Biol Stand; 1996; 88():15-8. PubMed ID: 9119129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Consumer risk assessment in case of maximum residue levels (MRLs) violations in food].
    Struciński P; Góralczyk K; Czaja K; Hernik A; Korcz W; Ludwicki JK
    Rocz Panstw Zakl Hig; 2007; 58(2):377-88. PubMed ID: 17929585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of needs for plasma for fractionation in Europe.
    Burckhardt JJ
    Biologicals; 1999 Dec; 27(4):337-41. PubMed ID: 10686061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biosafety and product release testing issues relevant to replication-competent oncolytic viruses.
    Wisher M
    Cancer Gene Ther; 2002 Dec; 9(12):1056-61. PubMed ID: 12522444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulatory expectation for data on viral testing and process evaluation for phase I studies and product licensing in the United States, Europe and Japan.
    Moriguchi H
    Dev Biol Stand; 1996; 88():143-7. PubMed ID: 9119127
    [No Abstract]   [Full Text] [Related]  

  • 32. Viral safety of biological products and the concept of validation.
    Horaud F
    Dev Biol Stand; 1996; 88():19-24. PubMed ID: 9119135
    [No Abstract]   [Full Text] [Related]  

  • 33. Quality standards of the European Pharmacopoeia.
    Bouin AS; Wierer M
    J Ethnopharmacol; 2014 Dec; 158 Pt B():454-7. PubMed ID: 25043777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality of alcohol-based hand disinfectants and their regulatory status. Development and marketing authorisation.
    Stengele M
    J Hosp Infect; 2008 Oct; 70 Suppl 1():49-54. PubMed ID: 18994682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. European regulation of herbal medicinal products on the border area to the food sector.
    Quintus C; Schweim HG
    Phytomedicine; 2012 Feb; 19(3-4):378-81. PubMed ID: 22070985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of botanicals in food supplements. Regulatory scope, scientific risk assessment and claim substantiation. 2005.
    Coppens P; Delmulle L; Gulati O; Richardson D; Ruthsatz M; Sievers H; Sidani S;
    Ann Nutr Metab; 2006; 50(6):538-54. PubMed ID: 17191027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The pharmacopoeia. An important pillar of drug safety].
    Belz S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Dec; 49(12):1205-11. PubMed ID: 17149662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three Rs potential in the development and quality control of immunobiologicals.
    Halder M
    ALTEX; 2001; 18 Suppl 1():13-47. PubMed ID: 11854853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Organic solvents in the pharmaceutical industry.
    Grodowska K; Parczewski A
    Acta Pol Pharm; 2010; 67(1):3-12. PubMed ID: 20210074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low levels of extraneous agents in vaccine starting materials.
    Rouby JC
    Biologicals; 2010 May; 38(3):354-7. PubMed ID: 20347331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.